安彩高科(600207.SH):定增事項獲得控股股東批覆
格隆匯9月22日丨安彩高科(600207.SH)公佈,公司已收到控股股東河南投資集團有限公司(“河南投資集團”)《河南投資集團有限公司關於河南安彩高科股份有限公司非公開發行股票的批覆》。河南投資集團根據《上市公司國有股權監督管理辦法》(國資委財政部證監會令第36號)要求,對公司非公開發行股票事項進行了批覆,批覆內容如下:
為支持河南安彩高科股份有限公司提升盈利能力,增強競爭力,原則同意安彩高科本次非公開發行股票的方案,發行股份數量不超過2.59億股(含本數),募集資金總金額不超過12億元人民幣(含本數),用於年產4800萬平方米光伏輕質基板項目及補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.